PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Royal DSM N.V.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DSM to Acquire Ocean Nutrition Canada to Expand its Nutritional Lipids Growth Platform - DSM (NYSE Euronext: DSM KON) to acquire Ocean Nutrition Canada in an all-cash transaction -
DSM to Acquire Ocean Nutrition Canada to Expand its Nutritional Lipids Growth Platform


NewswireToday - /newswire/ - Heerlen, NL, Netherlands, 2012/05/18 - DSM (NYSE Euronext: DSM KON) to acquire Ocean Nutrition Canada in an all-cash transaction - Euronext: DSM KON

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


• Total enterprise value CAD 540 million (about €420 million);
• Ocean Nutrition Canada expected 2012 Net Sales: approximately CAD 190 million with EBITDA of CAD 55-60 million;
• Ocean Nutrition Canada is a leader in fish-oil derived Omega-3 fatty acids for dietary supplements, highly complementary to DSM’s successful Martek acquisition in 2011;
• Strong strategic fit; acquisition will strengthen and complement DSM’s global Nutritional Lipids growth platform, based on healthy, polyunsaturated fatty acids (PUFAs);
• Acquisition extends DSM’s portfolio of omega-3 fatty acids reaching a wide range of different market segments and applications;
• Value creating acquisition; EPS accretive as from 2013.

Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has entered into a definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of CAD 540 million. Subject to customary conditions, the transaction is expected to close in H2 2012.

Ocean Nutrition Canada is a Canada-based supplier of fish-oil derived Omega-3 fatty acids (EPA and DHA) to the dietary supplement and food and beverage markets. The company is headquartered in Halifax (Nova Scotia, Canada) with approximately 415 employees. Ocean Nutrition Canada, founded in 1997, has production sites in Canada, the United States and Peru. Every day over 21 million servings of its MEG-3® product line are consumed in supplements and foods and beverages across the world. Net Sales for 2012 are expected at approximately CAD 190 million with an EBITDA of CAD 55-60 million. The average annual growth of the company over the past 5 years in local currency amounted to nearly 20%.

Strategic rationale
Supported by a growing body of scientific evidence, healthy PUFAs such as omega-3 fatty acids have been shown to provide significant health benefits supporting, for example, brain health, eye and cardiovascular health throughout life. Leading experts worldwide have noted that healthy PUFAs such as DHA, EPA and ARA are important nutrients for health throughout all stages of life, yet many consumers do not include enough in their daily diets. The rapidly growing nutritional lipids category is at an early stage yet well established and is based on strong science, offering significant growth opportunities across a broad range of market segments and applications.

Ocean Nutrition Canada is the world’s largest supplier of fish-derived Omega-3 fatty acids to the dietary supplement and food and beverage markets. Ocean Nutrition Canada’s fish derived Omega-3 products are highly complementary to DSM’s microbial DHA and ARA products as they address different customer needs and reach different market segments.

Given the very different value proposition and pricing of fish oil derived PUFAs (naturally occurring mixtures of DHA and EPA) compared to microbial derived PUFAs (DHA and ARA), these products do not compete. The acquisition of Ocean Nutrition Canada extends DSM’s portfolio of Omega-3 fatty acids reaching a wide range of different market segments and applications.

The acquisition will allow DSM to strengthen and complement its newly established, global Nutritional Lipids growth platform. It will strengthen DSM’s position in the North American dietary supplement market by adding fish oil derived omega-3 fatty acids to its portfolio and it will allow DSM to further leverage its global infrastructure to expand Ocean Nutrition Canada’s sales in dietary supplement markets outside North America and in the food and beverage markets worldwide. In addition, by leveraging forms, encapsulation and emulsification technologies, the range of applications and products can be expanded.

DSM expects the transaction to be EPS accretive as from 2013. The acquisition is expected to accelerate revenue growth through material revenue synergies with expanded distribution, marketing and product development. Customary operational efficiencies will also be realized in the integration process.

The acquisition of Ocean Nutrition Canada is the fifth acquisition in the Nutrition cluster since DSM in September 2010 announced its corporate strategy DSM in Motion: driving focused growth. These acquisitions form an integral part of DSM’s strategy for its Nutrition cluster and will contribute to the current and future growth of DSM’s attractive portfolio in health, nutrition and materials. The resulting stronger, more stable growth and profitability will enable DSM to continue to deliver shareholder value.

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, said: “After our successful acquisition of Martek in 2011, the acquisition of Ocean Nutrition Canada is the logical next step in developing our Nutritional Lipids into a major growth platform for our Nutrition cluster. Our science-based knowledge and expertise in nutritional ingredients will help to further grow Ocean Nutrition Canada’s business as part of DSM. This acquisition fully fits DSM’s strategy as we continue to create value for all stakeholders by providing innovative, sustainable solutions to the world’s greatest challenges.”

Stephan Tanda, member of the DSM Managing Board and responsible for the Nutrition cluster, commented: “We look forward to welcoming the very capable team of Ocean Nutrition Canada employees to DSM and to developing this exciting opportunity together. PUFAs have developed into a major nutrition ingredient category, based on solid science and well recognized health benefits, driving consistently high market growth rates. By combining Ocean Nutrition Canada’s strength in fish oil derived Omega-3s with our unique global infrastructure and broad access to dietary supplement and food & beverage markets, we will be able to provide our customers around the world with market leading value and a steadily widening range of applications.”

Martin Jamieson, President and CEO of Ocean Nutrition Canada, said: “ONC is a truly remarkable enterprise. From its founding in 1997 through to the present day, our Nova Scotia based company has led one of the most attractive growth segments of the global nutrition industry. In 15 short years the company has grown from start-up to global leader in fish oil derived Omega 3 and this acquisition by DSM, a leading international business with much greater scale and reach, is the logical next step in our evolution. Our success could not have been achieved without the talent and dedication of our 400 plus employees, the support and vision of our shareholders and the strong and well established relationships that the company has developed in the communities in which we operate. DSM is the right partner to guide our next phase of development and they will be great stewards of Ocean Nutrition going forward. We are delighted that they appropriately recognize the value of ONC’s worldwide market success, our leading edge technology platform and especially our immensely talented workforce.”

Conference calls
Today DSM ( will hold a conference call for the media from 08.00 AM – 08.30 AM CET (+31 (0)10 29 44 215 or +44 (0) 203 365 3207) and a conference call for investors and analysts from 09.00 AM – 10.00 AM CET (+31 (0)10 29 44 271 or +44 (0) 203 365 3207). Also, more information can be found in the presentation that can be found on DSM’s corporate website.

About Ocean Nutrition Canada
Ocean Nutrition Canada is the world's largest supplier of Omega-3 EPA/DHA ingredients to the dietary supplement and food manufacturing markets. Ocean Nutrition Canada also has the largest privately owned marine research and development facility in North America. Its MEG-3® branded ingredients offer high quality, odor-free, tasteless Omega-3 EPA/DHA from fish oil - the best source of Omega-3 EPA/DHA. By using clean, reliable, sustainable resources, Ocean Nutrition Canada provides its customers a competitive edge in the rapidly growing Omega-3 EPA/DHA market. Ocean Nutrition Canada customers also enjoy specialized services from critical technical and regulatory support to innovative R&D and global marketing support. Ocean Nutrition Canada is based in Nova Scotia, Canada.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Royal DSM N.V.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

DSM to Acquire Ocean Nutrition Canada to Expand its Nutritional Lipids Growth Platform

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Royal DSM N.V. |
Publisher Contact: Herman Betten - 
+31(0) 45 5782017 media.relations[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Royal DSM N.V. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Royal DSM N.V. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (